Esomeprazole ( DrugBank: Esomeprazole )

---

8 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
13	多発性硬化症／視神経脊髄炎	1
46	悪性関節リウマチ	5
86	肺動脈性肺高血圧症	1
98	好酸球性消化管疾患	3
107	若年性特発性関節炎	2
113	筋ジストロフィー	1
298	遺伝性膵炎	1
299	嚢胞性線維症	2

13. 多発性硬化症／視神経脊髄炎

---

臨床試験数 : 3,340 /  薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02205489 (ClinicalTrials.gov)	October 2014	29/7/2014	Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA	Single Arm Study To Assess Comprehensive Infusion Guidance For The Management Of The Infusion- Associated Reactions (IARs) In Relapsing-Remitting Multiple Sclerosis (RRMS) Patients Treated With LEMTRADA	Relapsing-remitting Multiple Sclerosis	Drug: Alemtuzumab GZ402673;Drug: cetirizine;Drug: ranitidine;Drug: methylprednisolone;Drug: aciclovir;Drug: esomeprazole;Drug: ibuprofen;Drug: paracetamol	Genzyme, a Sanofi Company	NULL	Completed	18 Years	N/A	Both	58	Phase 4	Belgium;France;Netherlands;Spain

46. 悪性関節リウマチ

---

臨床試験数 : 4,356 /  薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR-TCC-12002824	2008-07-10	2012-12-08	Traditional Chinese and anti-rheumatic drugs for the treatment of rheumatoid arthritis	Integration of Traditional Chinese and Western Medicine treat rheumatoid witharthritis: A prospective, randomized, controlled trial	rheumatoid arthritis with peptic ulcer	Acupuncture treatment:ARD treatment and concomitant ginger-partitioned moxibustion of the Zusanli acupoint. ;ARD treatment:esomeprazole magnesium enteric-coated tablets ,celecoxib capsules and methotrexate tablets ;Combined therapy:ARD treatment and concomitant ginger-partitioned moxibustion of the Zusanli acupoint + oral Shanhuang Wuji decoction ;	Hospital of Chengdu Military Area Command PLA	NULL	Completed	45	65	Both	Acupuncture treatment:20;ARD treatment:20;Combined therapy:20;		China
2	NCT00595517 (ClinicalTrials.gov)	October 2007	7/1/2008	Long Term Study to Investigate the Efficacy & Safety of D961H (Esomeprazole) for the Prevention of NSAIDs-induced Ulcer	A Long Term Study to Investigate the Efficacy and Safety Study of D961H (Esomeprazole) (20 mg Once Daily) for the Prevention of Gastric and/or Duodenal Ulcers Associated With Daily Nonsteroidal Anti-inflammatory Drug (NSAID) Use	Gastric Ulcer;Duodenal Ulcer;Rheumatoid Arthritis;Osteoarthritis;Lumbago	Drug: Esomeprazole 20 mg	AstraZeneca	NULL	Completed	20 Years	N/A	All	395	Phase 3	Japan
3	NCT00542789 (ClinicalTrials.gov)	August 2007	11/10/2007	Comparative Efficacy & Safety Study of Esomeprazole Versus Placebo for the Prevention of Gastric and Duodenal Ulcers With NSAID	A Phase III, Multicentre, Randomised, Double-blind, Parallel-group, Comparative Efficacy and Safety Study of Esomeprazole(20 mg Once Daily) Versus Placebo for the Prevention of Gastric and/or Duodenal Ulcers Associated With Daily Nonsteroidal Anti-inflammatory Drug (NSAID) Use	Gastric Ulcer;Duodenal Ulcer;Rheumatoid Arthritis;Osteoarthritis;Lumbago	Drug: Esomeprazole;Drug: Placebo	AstraZeneca	NULL	Completed	20 Years	N/A	All	343	Phase 3	Japan
4	JPRN-JapicCTI-080565		09/04/2008	A Long Term Study to Investigate the Efficacy and Safety Study of D961H (20 mg Once Daily) for the Prevention of Gastric and/or Duodenal Ulcers Associated With Daily Nonsteroidal Anti-Inflammatory Drug (NSAID) Use	A Long Term Study to Investigate the Efficacy and Safety Study of D961H (20 mg Once Daily) for the Prevention of Gastric and/or Duodenal Ulcers Associated With Daily Nonsteroidal Anti-Inflammatory Drug (NSAID) Use	Gastric Ulcer, Duodenal Ulcer, Rheumatoid Arthritis, Osteoarthritis, Lumbago	Intervention name : esomeprazole Dosage And administration of the intervention : Oral	AstraZeneca	NULL		20		BOTH		Phase 3	NULL
5	JPRN-JapicCTI-080531		21/02/2008	A Phase III, Multicentre, Randomised, Double-Blind, Parallel-Group, Comparative Efficacy and Safety Study of D961H (20 mg Once Daily) Versus Placebo for the Prevention of Gastric and/or Duodenal Ulcers Associated With Daily Nonsteroidal Anti-Inflammatory Drug (NSAID) Use	A Phase III, Multicentre, Randomised, Double-Blind, Parallel-Group, Comparative Efficacy and Safety Study of D961H (20 mg Once Daily) Versus Placebo for the Prevention of Gastric and/or Duodenal Ulcers Associated With Daily Nonsteroidal Anti-Inflammatory Drug (NSAID) Use	Gastric Ulcer, Duodenal Ulcer, Rheumatoid Arthritis, Osteoarthritis, Lumbago	Intervention name : esomeprazole Dosage And administration of the intervention : Oral	AstraZeneca	NULL		20		BOTH		Phase 3	NULL

先頭へ

86. 肺動脈性肺高血圧症

---

臨床試験数 : 1,205 /  薬物数 : 684 - (DrugBank : 124) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 193

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00963027 (ClinicalTrials.gov)	September 2009	19/8/2009	Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil	An Evaluation of Single Dose UT-15C SR (Treprostinil Diethanolamine) Pharmacokinetics Following Repeated Dosing With the Proton Pump Inhibitor Esomeprazole in Healthy Adult Volunteers	Hypertension, Pulmonary;Pulmonary Arterial Hypertension	Drug: Treprostinil diethanolamine;Drug: Esomeprazole	United Therapeutics	NULL	Completed	18 Years	55 Years	Both	30	Phase 1	United States

98. 好酸球性消化管疾患

---

臨床試験数 : 172 /  薬物数 : 149 - (DrugBank : 39) / 標的遺伝子数 : 38 - 標的パスウェイ数 : 135

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00728481 (ClinicalTrials.gov)	May 2008	15/7/2008	The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis	The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis	Eosinophilic Esophagitis;Gastroesophageal Reflux Disease;EE;GERD	Drug: Esomeprazole;Drug: Budesonide	Mayo Clinic	AstraZeneca	Completed	18 Years	80 Years	All	51	Phase 2/Phase 3	United States
2	NCT00895817 (ClinicalTrials.gov)	April 2008	6/5/2009	Fluticasone Versus Esomeprazole to Treat Eosinophilic Esophagitis	Comparison of Aerosolized Swallowed Fluticasone to Esomeprazole for the Treatment of Eosinophilic Esophagitis	Eosinophilic Esophagitis	Drug: Swallowed fluticasone;Drug: Esomeprazole	Walter Reed Army Medical Center	NULL	Completed	18 Years	N/A	All	42	N/A	United States
3	NCT00123656 (ClinicalTrials.gov)	August 2004	21/7/2005	Comparison of Esomeprazole to Aerosolized, Swallowed Fluticasone for Eosinophilic Esophagitis	Comparison of Esomeprazole to Aerosolized, Swallowed Fluticasone for Eosinophilic Esophagitis	Esophagitis	Drug: esomeprazole;Drug: fluticasone	University of Utah	American Society for Gastrointestinal Endoscopy	Completed	18 Years	80 Years	Both	30	Phase 2	United States

107. 若年性特発性関節炎

---

臨床試験数 : 447 /  薬物数 : 297 - (DrugBank : 57) / 標的遺伝子数 : 52 - 標的パスウェイ数 : 146

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01544114 (ClinicalTrials.gov)	April 2012	21/2/2012	A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)	A 6-month, Multicenter, Open-label, Safety Study of VIMOVO (250 mg/20 mg, 375 mg/20 mg, and 500 mg/20 mg Naproxen/Esomeprazole) in Adolescents Aged 12 to 16 Years, Inclusive, With Juvenile Idiopathic Arthritis (JIA)	Juvenile Idiopathic Arthritis (JIA)	Drug: VIMOVO 250/20;Drug: VIMOVO 375/20;Drug: VIMOVO 500/20	Horizon Pharma Ireland, Ltd., Dublin Ireland	NULL	Completed	12 Years	16 Years	All	46	Phase 4	United States
2	NCT01358383 (ClinicalTrials.gov)	May 2011	16/5/2011	Assessment of Pharmacokinetics of a Single Oral Dose of VIMOVO in Healthy Adult Volunteers	A Phase I, Open-label, Single-center Study to Assess the Pharmacokinetics of a Single Oral Dose of VIMOVO (250 mg Naproxen/20 mg Esomeprazole)in Healthy Adult Subjects	Juvenile Idiopathic Arthritis	Drug: naproxen;Drug: esomeprazole	AstraZeneca	NULL	Completed	18 Years	55 Years	Both	28	Phase 1	United States

113. 筋ジストロフィー

---

臨床試験数 : 646 /  薬物数 : 471 - (DrugBank : 105) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2019-004426-24-IT (EUCTR)	06/07/2020	15/06/2021	Deflazacort TREATment in LMNA related congenital muscular dystrophy: study of clinical effectiveness and search for reliable biomarkers.	Deflazacort TREATment in LMNA related congenital muscular dystrophy: study of clinical effectiveness and search for reliable biomarkers. - TREAT-LMNA	Congenital Muscolar distrophy LMNA related MedDRA version: 20.0;Level: LLT;Classification code 10003718;Term: Atrophy skeletal muscle;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Product Name: Deflazacort Product Code: [Deflazacort] INN or Proposed INN: deflazacort Trade Name: Lucen Product Name: Lucen Product Code: [-] INN or Proposed INN: esomeprazolo Other descriptive name: esomeprazole	AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	20	Phase 2	Italy

298. 遺伝性膵炎

---

臨床試験数 : 95 /  薬物数 : 148 - (DrugBank : 51) / 標的遺伝子数 : 53 - 標的パスウェイ数 : 142

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01142128 (ClinicalTrials.gov)	February 2009	9/6/2010	Viokase 16, Viokase16 Plus Nexium and Nexium Alone	A Randomized, Single Site, Double Blind, Fixed Dose, Cross Over Study of Viokase 16, Viokase16 Plus Nexium and Nexium Alone in the Reduction of Abdominal Pain in Patients With Chronic Pancreatitis	Chronic Pancreatitis	Drug: Nexium (esomeprazole magnesium);Drug: Placebo to Nexium;Drug: Viokase 16 (pancrelipase) + Nexium;Drug: Viokase 16 + placebo to Nexium	University of Florida	AstraZeneca	Terminated	18 Years	75 Years	All	12	Phase 1	United States

299. 嚢胞性線維症

---

臨床試験数 : 1,695 /  薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2007-004063-21-NL (EUCTR)	24/07/2008	31/10/2007	An open label, exploratory study on the effect of rhBSSL on the fat absorption in patients with cystic fibrosis and pancreatic insufficiency. - N/A	An open label, exploratory study on the effect of rhBSSL on the fat absorption in patients with cystic fibrosis and pancreatic insufficiency. - N/A	Cystic fibrosis and pancreatic insufficiency MedDRA version: 9.1;Level: LLT;Classification code 10011762;Term: Cystic fibrosis	Product Name: rhBSSL Product Code: rhBSSL INN or Proposed INN: Bucelipase alfa Trade Name: Nexium 20 Product Name: Nexium INN or Proposed INN: Esomeprazole	Biovitrum AB	NULL	Not Recruiting			Female: yes Male: yes	18		Netherlands
2	NCT01983774 (ClinicalTrials.gov)	February 2008	6/11/2013	Effect of Proton Pump Inhibitors on CF Pulmonary Exacerbations	Effect of Proton Pump Inhibitors on CF Exacerbations	Cystic Fibrosis	Drug: Esomeprazole;Drug: Placebo	Columbia University	NULL	Terminated	18 Years	65 Years	Both	13	Phase 2	United States

先頭へ